Open AccessImpact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse
Author(s) -
Pablo Labarga,
Pablo Barreiro,
José A. Mira,
Eugenia Vispo,
Norma Rallón,
Karin Neukam,
Ángela Camacho,
Antonio Caruz,
Sonia Rodrı́guez-Nóvoa,
Javier Pinilla,
Antonio Rivero,
José M. Benito,
Juan A. Pineda,
Vincent Soriano
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283471d83
Subject(s) - ribavirin , medicine , hepatitis c virus , odds ratio , confidence interval , gastroenterology , hepatitis c , hepacivirus , virology , virus , immunology
IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)].